Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 15/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | SCN4A | P35499 | 1/20 | 0.43 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 5/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.40 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3691734 | 0.84 | LMNA (0.55) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL5367306 | 0.84 | LMNA (0.42) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL1248214 | 0.84 | P2RX4 (0.46) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL5367522 | 0.81 | P2RX4 (0.37) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL10653232 | 0.80 | LMNA (0.39) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL8672568 | 0.76 | P2RX4 (0.46) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL5172363 | 0.76 | BCHE (0.46) | P2RX4LMNATSHRMAPK1SCN4A | |
| SCHEMBL9389647 | 0.75 | L3MBTL1 (0.50) | P2RX4LMNATSHRSMN1; SMN2KMT2A | |
| SCHEMBL1133635 | 0.74 | P2RX4 (0.41) | P2RX4LMNATSHRMAPK1SCN4A | |
| Hydrochloric Acid SCHEMBL29383470 | 0.73 | P2RX4 (0.40) | P2RX4LMNATSHRMAPK1SCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007146230-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2007-12-21 | — | — | WO | claimed |
| EP-3052492-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | Cancer Research Technology Limited (GB) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049535-A1 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2015-04-09 | — | — | WO | disclosed |
| EP-2396329-A1 | Compounds for the treatment of hepatitis c | Bristol-Myers Squibb Company (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010093359-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-19 | — | — | WO | disclosed |
| EP-2209789-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-07-28 | — | — | EP | disclosed |
| EP-2183252-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-2178878-A1 | TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2121694-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | Bristol-Myers Squibb Company (US) | 2009-11-25 | — | — | EP | disclosed |
| WO-2009067108-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009029384-A2 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-2029606-A2 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | Brystol-Myers Squibb Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2009023487-A1 | TETRACYCLIC COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-19 | — | — | WO | disclosed |
| EP-1987038-A2 | HCV NS5B INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2008111978-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2007140254-A2 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007092888-A2 | HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007033175-A1 | INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |